News Conference News ACC 2024 Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It Michael O'Riordan March 27, 2024
News Conference News ACC 2023 Diabetic Patients in Middle East, Africa Overburdened by ASCVD Michael O'Riordan March 14, 2023
News Conference News ACC 2023 IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF L.A. McKeown March 14, 2023
News Conference News ACC 2023 Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR Michael O'Riordan March 13, 2023
News Conference News ACC 2023 Tailored Alerts Up High-Intensity Statin Prescribing: PCDS Statin Yael L. Maxwell March 13, 2023
News Conference News ACC 2023 Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2 Michael O'Riordan March 09, 2023
News Conference News ACC 2023 Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT Yael L. Maxwell March 07, 2023
News Conference News ACC 2023 No Downside to Immediate Complete Revascularization in ACS: BIOVASC Michael O'Riordan March 06, 2023
News Conference News ACC 2022 POISE-3: Two Perioperative BP Strategies Give Similar Results in Noncardiac Surgery Todd Neale April 06, 2022
News Conference News ACC 2022 ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI Todd Neale April 05, 2022
News Conference News ACC 2021 Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM L.A. McKeown May 16, 2021
News Conference News ACC 2020 Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT Todd Neale April 02, 2020
News Conference News ACC 2020 Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events Michael O'Riordan April 02, 2020
News Conference News ACC 2020 ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up Shelley Wood March 30, 2020
News Conference News ACC 2018 Salt in the Wound: Experts Clash Over Ideal Sodium Targets in Hypertension Michael O'Riordan March 15, 2018
News Conference News ACC 2017 ORION-1: Novel LDL-Lowering Treatment Could Reduce Costs, Increase Adherence Over PCSK9s Yael L. Maxwell March 17, 2017
News Conference News ACC 2017 FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017
News Conference News ACC 2013 Aspirin Alone Just as Good as Dual Antiplatelet Therapy Beyond 12 Months Jason Kahn March 11, 2013